Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
30°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
PureTech Health plc - American Depositary Shares
(NQ:
PRTC
)
17.55
-1.17 (-6.25%)
Streaming Delayed Price
Updated: 3:20 PM EST, Jan 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PureTech Health plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Today 7:00 EST
From
PureTech Health plc
Via
Business Wire
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Appoints UBS as UK Corporate Broker
January 06, 2025
From
PureTech Health plc
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 16, 2024
Via
Benzinga
PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients
December 16, 2024
PureTech Health's Phase 2b trial of deupirfenidone for IPF met its primary endpoint, showing significant lung function improvement and dose-dependent benefits.
Via
Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
December 16, 2024
Via
Benzinga
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
December 16, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
December 11, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
December 09, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
November 20, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
November 05, 2024
From
PureTech Health plc
Via
Business Wire
PureTech to Present at Two Upcoming Investor Conferences
October 30, 2024
From
PureTech Health
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
October 21, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
October 09, 2024
From
PureTech Health plc
Via
Business Wire
PureTech to Present at CHEST 2024 Annual Meeting
October 01, 2024
From
PureTech Health
Via
Business Wire
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
September 27, 2024
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without...
Via
Benzinga
Exposures
Product Safety
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
September 27, 2024
From
PureTech Health plc
Via
Business Wire
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 10, 2024
Via
Benzinga
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 06, 2024
From
PureTech Health plc
Via
Business Wire
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 03, 2024
Via
Benzinga
PureTech Health plc – Half-Year Report
August 28, 2024
From
PureTech Health plc
Via
Business Wire
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
August 26, 2024
Via
Benzinga
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
August 22, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Health: Notice of Half-Yearly Results
August 21, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
August 13, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
July 23, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Health: Completion of Tender Offer & Total Voting Rights
June 24, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Health: Results of the Tender Offer
June 24, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Announces Change of Board Role
June 20, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
June 18, 2024
From
PureTech Health plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.